Abpro Holdings, Celltrion to present preclinical data for CT-P72/ABP-102

Abpro Corporation and Celltrion announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer 2025 Annual Meeting, being held November 6-10, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. Following a prior oral presentation at the American Association of Cancer Research New Drugs on the Horizon Session earlier this year, these additional preclinical results will be featured at SITC 2025, highlighting the growing body of evidence supporting CT-P72/ABP-102’s advancement toward first-in-human studies. Key Findings: Selective tumor binding: CT-P72/ABP-102 binds selectively to HER2 high tumor cells with reduced binding to HER2-expressing normal tissues while binding CD3 on T cells with reduced affinity for added safety. Potent, Selective Anti-Tumor Activity: The molecule demonstrated robust T-cell activation, PBMC-mediated cytotoxicity, and cytokine release in vitro using human PBMCs. Potency was preserved in HER2-high tumor target cells but was reduced in HER2-low cells, which are typical of normal tissues, confirming enhanced tumor selectivity. Strong preclinical activity in vivo including in Enhertu-resistant models: In vivo, CT-P72/ABP-102 inhibited the growth of HER2-high BT-474 tumors in a dual xenograft model and demonstrated efficacy in both an Enhertu-resistant gastric cancer model and the KPL4 xenograft model. Favorable Safety Profile: A GLP repeated-dose toxicity study in cynomolgus monkeys demonstrated good tolerability at all tested doses, including the highest dose, supporting a favorable safety profile in non-human primates.